Barbara Onumah, MD
Endocrinology, Diabetes & Metabolism · Annapolis, MDNPI 1548456379
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,990 of the $11,920 with a category attached, or 67.0%. 32 manufacturers reported payments, led by Eli Lilly at 43.6% of the total.
Across 187 payments — averaging $63.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$5K
- Novo Nordisk$3K
- Lilly USA, LLC$950
- Xeris Pharmaceuticals, Inc.$441
- Corcept Therapeutics$326
- Insulet Corporation$213
- plus $2K from 26 others
What the payments were for
- Consulting fees$7,99067%
- Food & beverage$3,90733%
- Education$220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 2 | $5,200 |
| Novo Nordisk | 11 | $3,012 |
| Lilly USA, LLC | 45 | $950 |
| Xeris Pharmaceuticals, Inc. | 26 | $441 |
| Corcept Therapeutics | 14 | $326 |
| Insulet Corporation | 7 | $213 |
| Sanofi-aventis U.S. LLC | 11 | $190 |
| Dexcom, Inc. | 8 | $185 |
| Cequr Corporation | 3 | $144 |
| Amneal Pharmaceuticals LLC | 7 | $125 |
| Amgen | 6 | $124 |
| AbbVie | 6 | $113 |
| Medtronic | 4 | $104 |
| Tandem Diabetes Care, Inc. | 4 | $95 |
| AstraZeneca(2 entities) | 4 | $87 |
| Ascendis Pharma Endocrinology Inc | 4 | $84 |
| Boehringer Ingelheim | 4 | $81 |
| Recordati_rare_diseases_inc. | 3 | $65 |
| Madrigal Pharmaceuticals | 2 | $62 |
| Bayer | 2 | $44 |
| Abbott | 2 | $43 |
| BD | 2 | $39 |
| Antares Pharma, Inc. | 1 | $31 |
| Vivus LLC | 1 | $29 |
| Amphastar Pharmaceuticals, Inc. | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| BETA Bionics, Inc. | 1 | $18 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
| Embecta Corp. | 1 | $17 |
| Ascensia Diabetes Care US Inc. | 1 | $14 |
| Gilead | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$2,790
How this compares
$11,920 in reported general payments places this provider in the 85th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
See all endocrinology, diabetes & metabolism providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 100 | $182,766 |
| JardianceEmpagliflozin | 139 | $170,516 |
| MounjaroTirzepatide | 88 | $143,791 |
| TrulicityDulaglutide | 53 | $76,171 |
| Tresiba Flextouch U-200Insulin Degludec | 36 | $48,040 |
| FarxigaDapagliflozin Propanediol | 23 | $28,024 |
| Tresiba Flextouch U-100Insulin Degludec | 34 | $21,115 |
| RybelsusSemaglutide | 12 | $12,775 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 27 | $12,470 |
| Victoza 3-PakLiraglutide | 12 | $10,828 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 76 | $7,136 |
| Humalog Kwikpen U-100Insulin Lispro | 22 | $6,900 |
| Cinacalcet Hcl | 35 | $5,571 |
| Novolog FlexpenInsulin Aspart | 24 | $4,081 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $4,017 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $950 | $219,962141 claims |
| Novo NordiskOzempic, Rybelsus | $3,012 | $195,541112 claims |
| Boehringer IngelheimJardiance | $81 | $170,516139 claims |
| AstraZenecaFarxiga | $87 | $28,02423 claims |
| AbbVieSynthroid | $113 | $3,94655 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $125 | $1,16982 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
Other endocrinology, diabetes & metabolism in Annapolis
- Eyob MakonnenAnnapolis$205K
- Darshana PurohitAnnapolis$25K
- Kavita IyengarAnnapolis$9K
- Jocelyn UriosteguiAnnapolis$7K
- Daniel GozziSuitland$1.2M
- Martin SarkarFrederick$1.1M
- Nicholas ArgentoLaurel$1.1M
- Romeu AzevedoCamp Springs$987K
- David BrownRockville$497K
- Philip LevinBaltimore$489K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.